

SALT LAKE COUNTY

Board Member Nomination/Application

Board: SACBAC Date: _____

Nominated By (if applicable): _____

Nominee's Name MARTIN GREGORY

Home Address: _____ City, State, Zip: _____

Work Address: _____

Home Phone: _____ Work Phone: _____ E-Mail: _____

Would applicant prefer work or home phone/address used as mailing address? Home

Salt Lake County Council District #: 2

(To find the district you live in go to <http://vote.utah.gov/elected-officials/>, enter your address and zip code, then click on **Find**. The results will produce a map with a **red diamond** at your home location. Click on the diamond and wait for a text box to appear containing your elected officials. Scroll down until you see the **fourth** County Council representative (not "At-Large") and list that name above.)

I prefer that my personal contact information remain private and protected ☒

Unique qualifications and/or perspectives you would bring to a Board or Commission:

Board Coordinator Staff Section

Salt Lake County does not discriminate on the basis of race, color, national origin, sex, sexual orientation, age, religion, marital status, or disability.

Is this a (check one): ☐ reappointment ☐ fill vacant seat ☐ new seat added to board

If filling a vacant seat, why?

☐ Term expired (expiration date: _____) ☐ Member Resigned

☐ Other _____

Name of board member being replaced: _____

This is a _____ year term. Term will begin _____ of _____ and end _____ of _____

Comments: _____

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Martin C. Gregory

eRA COMMONS USER NAME (credential, e.g., agency login): [REDACTED]

POSITION TITLE: Professor (Clinical) of Internal Medicine, School of Medicine, University of Utah

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Otago	B.Med.Sciences	11/1962	Premedical Sciences
University of Oxford	B.A.	10/1966	
University of Oxford	M.D.	12/1968	Medicine
Radcliffe Infirmary	Intern	06/1970	General Medicine/Surgery
Churchill Hospital	Fellow	07/1971	Neph-Hypertension
Hammersmith	Resident	07/1971	Internal Medicine
University of Oxford	M.A.	10/1971	Physiology
Radcliffe Infirmary	Fellow	06/1974	Nephrology
University of Oxford	Ph.D.	02/1975	
Hopital Necker	Resident	06/1975	Nephrology
Churchill Hospital	Resident	06/1976	Neurology

A. Personal Statement

I began my medical training at the University of Otago, New Zealand where I received the degree of Bachelor of Medical Sciences. I completed my BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. I completed additional training in Medicine and Nephrology from the University of London and at Oxford University. I completed my residency and then fellowship in Nephrology at Oxford University. I received further nephrology training at the University of Paris (VI). I am board certified in Internal Medicine and Nephrology. In the past, I served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. I am currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

I have served on editorial boards of the Archives of Internal Medicine, Journal of the American Society of Nephrology, Transactions of the American Society for Artificial Internal Organs, Kidney International, and New England Journal of Medicine. I am an internationally recognized expert in Alport syndrome. I was a member of the team who described the first mutations in X-linked Alport syndrome and have collaborated in developing methods for diagnosing Alport syndrome by examining type IV collagen chains in kidney and skin biopsies. I have published numerous articles and book chapters related to Nephrology and the genetics of Alport syndrome.

B. Positions and Honors**Positions and Employment**

1973-1974 Consultant in Medicine, Oxford Regional Hospital, Oxford OX1

1976-1979	Head, Groote Schuur Hospital, Renal Unit, Cape Town
1976-1979	Senior Lecturer in Medicine, University of Cape Town, Cape Town
1979-1980	Renal Physician, Auckland Hospital, Auckland
1980-1982	Visiting Associate Professor and Acting Head, University of Utah School of Medicine, Division of Nephrology, Salt Lake City, UT
1982-1983	Consultant Nephrologist, St. Philip's Hospital, London, England
1982-1983	Senior Lecturer, University of London, Institute of Urology, London, England
1983-1989	Associate Professor of Medicine, University of Utah School of Medicine, Division of Nephrology, Salt Lake City, UT
1989-1992	Professor of Medicine (Clinical), University of Utah School of Medicine, Division of Nephrology, Salt Lake City, UT
1992-2000	Professor of Medicine (Clinical), University of Utah School of Medicine, Division of General Internal Medicine, Salt Lake City, UT
1996-1999	Director, Freshman and Sophomore Physical Diagnosis Course, University of Utah, Salt Lake City, UT
2000-2001	Professor of Medicine (Clinical), University of Utah School of Medicine, Division of Nephrology, Salt Lake City, UT
2001-2002	Director of Dialysis Services, King Edward VII Memorial Hospital, Bermuda
2002-	Professor of Medicine (Clinical) and Associate Division Chief, University of Utah School of Medicine, Division of Nephrology, Salt Lake City, UT
2006-	Professor of Pediatrics (Adjunct), Division of Pediatric Nephrology, University of Utah School of Medicine, Salt Lake City, UT

Honors

1958	Universities of New Zealand Junior National Scholarship
1959	Universities of New Zealand Junior National Scholarship
1963	University of Otago. A.J.F. Mickle Scholarship
1964-1968	University of Oxford. Commonwealth Medical Scholarship
1966	University of Oxford. Senior Hulme Scholarship (Brasenose College)
1968	Royal College of Surgeons, Faculty of Ophthalmologists Undergraduate Prize
1968	University of Oxford. Radcliffe Infirmary Prize in Pathology
1972-1975	University of London, Beit Memorial Fellowship
1990	University of Utah Physician Assistant Program. Outstanding Teaching Award
1991-1992	American Association of Medical Colleges, Organization of Student Representatives Teaching Award
1992	University of Utah School of Medicine - Class of 1992, Outstanding Pre-Clinical Faculty Award
1994-1995	Outstanding Teaching Award, Department of Internal Medicine, University of Utah
1994-1995	American Association of Medical Colleges, Organization of Student Representatives Teaching Award
1995	University of Utah Physician Assistant Program. Outstanding Teaching Award
1998	University of Utah School of Medicine - Class of 1998, Outstanding Clinical Faculty Award
2006-	Exemplary Humanitarian and Community Service Award, National Kidney Foundation of Utah and Idaho
2006-	Outstanding Faculty Teaching Award, Department of Internal Medicine, University of Utah
2016-	Humanitarian Award, National Kidney Foundation of Utah and Idaho

C. Contribution to Science

- 1) I am an internationally recognized expert in Alport syndrome. I have published many articles and book chapters related to Nephrology and the genetics of Alport syndrome. I have identified several pathogenic mutations in Alport syndrome which has significant impact in terms of diagnosing and treating the disease. Over the course of 40 years, I have collected samples, clinical information and pedigrees of 130 families with X-linked Alport syndrome.

- A) Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38.

- B) Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010). Genotype-phenotype correlation in X-linked Alport syndrome. *J Am Soc Nephrol*, 21(5), 876-83.
- C) Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013). Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. *Pediatr Nephrol*, 28(1), 5-11.
- D) Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. *Science*, 248(4960), 1224-7.

2) I have been involved in hemodialysis research since 1990 with a clinical and translational focus in this area. My areas of clinical research interests focus on epidemiologic and observational studies, and clinical trials. I have been interested in dialysis issues relevant to developing world.

- A) Cheung AK, Gregory MC (1985). Subclavian vein thrombosis in hemodialysis patients. *Trans Am Soc Artif Intern Organs*, Am Soc Artif Intern Organs, 31, 131-5.
- B) Ekins BR, Rollins DE, Duffy DP, Gregory MC (1985). Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. *West J Med*, 142(3), 337-40.
- C) Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC (1990). Type of hemodialysis and preference for behavioral involvement: interactive effects on adherence in end-stage renal disease. *Health Psychol*, 9(2), 225-36.
- D) Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC, Rich MA (1992). Family support, physical impairment, and adherence in hemodialysis: an investigation of main and buffering effects. *J Behav Med*, 15(4), 313-25.

3) I have published several literature review articles and book chapters given my role as a clinical educator. I have published in the field of urine analysis, acid base balance and hereditary diseases.

- A) Kinniburgh DW, Ash KO, Gregory MC (1983). Should routine microscopic examination of urine be discontinued? *Clin Chem*, 29(1), 212-3.
- B) Gregory MC, Morgan SH (1994). Fabry's Disease. In Greenberg A (Ed.), *A Primer of Nephrology* (pp. 206-210). National Kidney Foundation.
- C) Gregory MC, Atkin CL (1997). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. In Schrier RW, Gottschalk CW (Eds.), *Diseases of the Kidney* (6th Ed, pp. 561-590). Little Brown, Boston.
- D) Gregory MC (2001). Urinalysis. In Jones SL (Ed.), *Clinical Laboratory Pearls* (pp. 326-336). Philadelphia: Lippincott Williams and Wilkins.

D. Additional Information: Research Support and/or Scholastic Performance

FUNDING

Active Grants

10/31/17 – 11/01/2020	Reata Cardinal 402-C-1603 Role: Principal Investigator
-----------------------	---

Pending Grants

03/01/18-02/28/22	Regulus Therapeutics Inc. Rg012-03 Role: Principal Investigator
-------------------	--

Past Grants

01/01/08 – 06/30/08	Astor Project University of Minnesota Role: Principal Investigator
10/01/08 – 09/30/09	Astor Project

07/01/11 – 06/30/12	University of Minnesota Role: Principal Investigator Passive Flow Dialysis National Kidney Foundation of Utah
07/01/12 – 06/30/13	Role: Principal Investigator Passive Flow Dialysis National Kidney Foundation of Utah
09/15/12 – 06/30/15	Role: Principal Investigator Alport Feasibility Study University of Minnesota Role: Principal Investigator



Board Appointment Approval

Ben McAdams

Salt Lake County Mayor

Erin Litvack

Deputy Mayor, County Services

Rick Graham

Deputy Mayor, Operations

Karen Hale

Deputy Mayor, Community
& External Affairs

Darrin Casper

Deputy Mayor, Finance
& Administration

On the 4th day of December 2018 the Salt Lake County Council consents to the reappointment of Mr. Martin Gregory as a member of the *Salt Lake County Bicycle Advisory Committee*.

His second, three-year term began January 1, 2018 and will end December 31, 2020.

Salt Lake County Council

Aimee Winder Newton
Chair, Salt Lake County Council

Attest:

Sherrie Swensen, County Clerk

Please instruct the Council Clerk to return this form to Anna Vukin-Chow in the Mayor's Office, N2- 100 to process this appointment.